Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adenocarcinoma | 9 | 2024 | 1018 | 1.730 |
Why?
|
| Pancreatic Neoplasms | 6 | 2024 | 728 | 1.320 |
Why?
|
| Colorectal Neoplasms | 5 | 2025 | 637 | 0.860 |
Why?
|
| Circulating Tumor DNA | 2 | 2022 | 39 | 0.830 |
Why?
|
| Oncolytic Viruses | 1 | 2024 | 76 | 0.810 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 234 | 0.750 |
Why?
|
| Ikaros Transcription Factor | 2 | 2022 | 32 | 0.720 |
Why?
|
| Transaminases | 2 | 2022 | 36 | 0.710 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2023 | 168 | 0.690 |
Why?
|
| Anemia | 1 | 2024 | 351 | 0.650 |
Why?
|
| Needs Assessment | 2 | 2025 | 179 | 0.600 |
Why?
|
| Colonic Neoplasms | 2 | 2019 | 264 | 0.600 |
Why?
|
| Safety-net Providers | 1 | 2020 | 71 | 0.600 |
Why?
|
| Oncologists | 1 | 2019 | 31 | 0.590 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2018 | 64 | 0.570 |
Why?
|
| Documentation | 1 | 2019 | 121 | 0.570 |
Why?
|
| Exophthalmos | 1 | 2018 | 30 | 0.560 |
Why?
|
| Minority Groups | 1 | 2020 | 250 | 0.550 |
Why?
|
| Orbital Neoplasms | 1 | 2018 | 48 | 0.540 |
Why?
|
| Bacteremia | 2 | 2021 | 428 | 0.540 |
Why?
|
| Neuroendocrine Tumors | 1 | 2018 | 58 | 0.530 |
Why?
|
| Orbit | 1 | 2018 | 84 | 0.530 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 482 | 0.530 |
Why?
|
| Cholangiocarcinoma | 1 | 2018 | 121 | 0.530 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 127 | 0.530 |
Why?
|
| Neoadjuvant Therapy | 6 | 2023 | 402 | 0.520 |
Why?
|
| Rectal Neoplasms | 3 | 2023 | 81 | 0.500 |
Why?
|
| Oncolytic Virotherapy | 1 | 2017 | 89 | 0.490 |
Why?
|
| Stomach Neoplasms | 3 | 2019 | 565 | 0.480 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2014 | 5 | 0.450 |
Why?
|
| Cholestasis, Extrahepatic | 1 | 2014 | 7 | 0.450 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2014 | 23 | 0.440 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 558 | 0.420 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 1347 | 0.400 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 761 | 0.390 |
Why?
|
| Physicians | 1 | 2019 | 635 | 0.380 |
Why?
|
| Electronic Health Records | 1 | 2019 | 802 | 0.370 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 3 | 2018 | 65 | 0.360 |
Why?
|
| Neoplasms | 2 | 2025 | 2944 | 0.330 |
Why?
|
| Neoplasm Staging | 7 | 2023 | 1367 | 0.310 |
Why?
|
| Aged | 13 | 2025 | 21379 | 0.300 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 1394 | 0.280 |
Why?
|
| Aspergillosis | 2 | 2004 | 46 | 0.270 |
Why?
|
| Middle Aged | 14 | 2025 | 28888 | 0.270 |
Why?
|
| Lymphatic Metastasis | 2 | 2019 | 443 | 0.260 |
Why?
|
| Adult | 16 | 2025 | 31618 | 0.260 |
Why?
|
| Humans | 30 | 2025 | 132334 | 0.250 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 688 | 0.250 |
Why?
|
| Paclitaxel | 2 | 2024 | 140 | 0.250 |
Why?
|
| Anal Canal | 2 | 2023 | 82 | 0.250 |
Why?
|
| Aspergillus | 1 | 2004 | 26 | 0.230 |
Why?
|
| Mannans | 1 | 2004 | 15 | 0.230 |
Why?
|
| Female | 16 | 2025 | 70786 | 0.220 |
Why?
|
| Lung Diseases, Fungal | 1 | 2004 | 37 | 0.220 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2004 | 149 | 0.220 |
Why?
|
| Male | 16 | 2025 | 65052 | 0.220 |
Why?
|
| Albumins | 1 | 2024 | 96 | 0.210 |
Why?
|
| Health Services Needs and Demand | 1 | 2025 | 174 | 0.210 |
Why?
|
| Bayes Theorem | 1 | 2024 | 309 | 0.190 |
Why?
|
| Communicable Diseases | 1 | 2004 | 160 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 1126 | 0.190 |
Why?
|
| Cost-Benefit Analysis | 2 | 2015 | 557 | 0.180 |
Why?
|
| Blood Culture | 1 | 2021 | 36 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 1556 | 0.170 |
Why?
|
| Gastrointestinal Diseases | 1 | 2004 | 359 | 0.170 |
Why?
|
| DNA Methylation | 2 | 2025 | 1132 | 0.170 |
Why?
|
| Aged, 80 and over | 6 | 2025 | 7111 | 0.170 |
Why?
|
| Cancer Vaccines | 1 | 2022 | 188 | 0.160 |
Why?
|
| Lymph Nodes | 2 | 2019 | 388 | 0.160 |
Why?
|
| Stress, Psychological | 1 | 2025 | 577 | 0.160 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 198 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 1303 | 0.160 |
Why?
|
| Fraud | 1 | 2019 | 17 | 0.160 |
Why?
|
| Epigenesis, Genetic | 1 | 2025 | 759 | 0.160 |
Why?
|
| Acute Disease | 2 | 2018 | 1176 | 0.150 |
Why?
|
| Medically Uninsured | 1 | 2020 | 75 | 0.150 |
Why?
|
| Carcinoma, Small Cell | 1 | 2019 | 42 | 0.150 |
Why?
|
| Genetic Therapy | 1 | 2024 | 720 | 0.150 |
Why?
|
| Leucovorin | 3 | 2023 | 54 | 0.150 |
Why?
|
| DNA Mismatch Repair | 1 | 2018 | 54 | 0.150 |
Why?
|
| Mass Screening | 2 | 2015 | 831 | 0.150 |
Why?
|
| Fluorouracil | 3 | 2023 | 139 | 0.140 |
Why?
|
| Physical Examination | 1 | 2019 | 166 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2169 | 0.140 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 332 | 0.140 |
Why?
|
| Gastrectomy | 1 | 2019 | 102 | 0.140 |
Why?
|
| Genetic Testing | 2 | 2015 | 1098 | 0.140 |
Why?
|
| Myxoma virus | 1 | 2017 | 1 | 0.140 |
Why?
|
| Parvovirus | 1 | 2017 | 8 | 0.140 |
Why?
|
| Orthoreovirus, Mammalian | 1 | 2017 | 7 | 0.140 |
Why?
|
| Algorithms | 2 | 2015 | 1720 | 0.130 |
Why?
|
| Measles virus | 1 | 2017 | 16 | 0.130 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2018 | 78 | 0.130 |
Why?
|
| Vaccinia virus | 1 | 2017 | 49 | 0.130 |
Why?
|
| Simplexvirus | 1 | 2017 | 100 | 0.130 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 901 | 0.130 |
Why?
|
| Retrospective Studies | 5 | 2021 | 17363 | 0.130 |
Why?
|
| Immunotherapy | 1 | 2022 | 748 | 0.130 |
Why?
|
| Ethics, Medical | 1 | 2019 | 401 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2023 | 399 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 478 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 1247 | 0.110 |
Why?
|
| Histocytochemistry | 1 | 2014 | 92 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2014 | 64 | 0.110 |
Why?
|
| Adenoviridae | 1 | 2017 | 596 | 0.110 |
Why?
|
| Radiography, Thoracic | 1 | 2014 | 153 | 0.110 |
Why?
|
| Microscopy | 1 | 2014 | 125 | 0.100 |
Why?
|
| Esophagoscopy | 1 | 2014 | 167 | 0.100 |
Why?
|
| Organ Sparing Treatments | 2 | 2023 | 43 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 1153 | 0.090 |
Why?
|
| Deoxycytidine | 2 | 2023 | 83 | 0.090 |
Why?
|
| Health Status Disparities | 1 | 2015 | 251 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1723 | 0.080 |
Why?
|
| Chemoradiotherapy | 2 | 2023 | 125 | 0.080 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 1297 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 2556 | 0.080 |
Why?
|
| Preoperative Care | 2 | 2023 | 370 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2023 | 956 | 0.070 |
Why?
|
| Treatment Outcome | 5 | 2023 | 13016 | 0.060 |
Why?
|
| Foodborne Diseases | 1 | 2004 | 12 | 0.060 |
Why?
|
| Meningococcal Vaccines | 1 | 2005 | 30 | 0.060 |
Why?
|
| Biomarkers, Tumor | 2 | 2025 | 1683 | 0.060 |
Why?
|
| Protozoan Infections | 1 | 2004 | 16 | 0.060 |
Why?
|
| Galactose | 1 | 2004 | 57 | 0.060 |
Why?
|
| Splenectomy | 1 | 2005 | 62 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 250 | 0.060 |
Why?
|
| Itraconazole | 1 | 2003 | 24 | 0.050 |
Why?
|
| Young Adult | 4 | 2019 | 9945 | 0.050 |
Why?
|
| Fluconazole | 1 | 2003 | 50 | 0.050 |
Why?
|
| Organoplatinum Compounds | 1 | 2023 | 33 | 0.050 |
Why?
|
| Pneumococcal Vaccines | 1 | 2005 | 172 | 0.050 |
Why?
|
| Age of Onset | 1 | 2025 | 626 | 0.050 |
Why?
|
| Preoperative Period | 1 | 2023 | 92 | 0.050 |
Why?
|
| Survival Rate | 2 | 2019 | 2187 | 0.050 |
Why?
|
| Antibodies, Bacterial | 1 | 2005 | 406 | 0.050 |
Why?
|
| Pneumococcal Infections | 1 | 2005 | 277 | 0.050 |
Why?
|
| Social Support | 1 | 2025 | 386 | 0.050 |
Why?
|
| Streptococcus pneumoniae | 1 | 2005 | 381 | 0.050 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2022 | 23 | 0.050 |
Why?
|
| Virus Diseases | 1 | 2004 | 291 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2003 | 248 | 0.050 |
Why?
|
| Bacterial Infections | 1 | 2004 | 324 | 0.050 |
Why?
|
| Psychometrics | 1 | 2025 | 693 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 211 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2003 | 311 | 0.040 |
Why?
|
| Standard of Care | 1 | 2022 | 135 | 0.040 |
Why?
|
| Incidence | 3 | 2017 | 3361 | 0.040 |
Why?
|
| Registries | 2 | 2019 | 1585 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 2145 | 0.040 |
Why?
|
| Caregivers | 1 | 2025 | 598 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 297 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 68 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 2019 | 89 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2019 | 87 | 0.040 |
Why?
|
| Prognosis | 2 | 2019 | 5009 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2019 | 166 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2019 | 145 | 0.040 |
Why?
|
| Recurrence | 1 | 2022 | 1458 | 0.040 |
Why?
|
| United States | 3 | 2019 | 11627 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2022 | 1570 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 302 | 0.040 |
Why?
|
| Rectum | 1 | 2018 | 114 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2019 | 425 | 0.030 |
Why?
|
| General Surgery | 1 | 2019 | 216 | 0.030 |
Why?
|
| Stomach | 1 | 2019 | 272 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2004 | 1192 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 3742 | 0.030 |
Why?
|
| Animals | 1 | 2017 | 34989 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2019 | 1256 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2025 | 5150 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 1451 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 3980 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 1230 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1605 | 0.030 |
Why?
|
| Biomarkers | 1 | 2023 | 3389 | 0.030 |
Why?
|
| Quality of Life | 1 | 2023 | 2151 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 2303 | 0.020 |
Why?
|
| Adolescent | 2 | 2019 | 20552 | 0.020 |
Why?
|
| Texas | 1 | 2017 | 3628 | 0.020 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2005 | 25 | 0.010 |
Why?
|
| Drug Resistance, Fungal | 1 | 2003 | 30 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 3358 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 803 | 0.010 |
Why?
|
| Risk Factors | 1 | 2015 | 10910 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2003 | 621 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2005 | 3139 | 0.010 |
Why?
|